.

Here are some of the pharmaceutical companies in which the Foreign Institutional Investors (FII) / Foreign Portfolio Investors (FPI) have increased their holding stake in the company which indicates that they are positive and confident about the company’s performance and future outlook, thereby facilitating financial innovation and growth in capital markets. 

Alkem Laboratories 

Alkem Laboratories Limited is engaged in the business of the development, manufacture, and sale of pharmaceutical and nutraceutical products across therapeutic areas like dermatology, diabetology, cardiology, oncology, urology, and many more. 

With a market capitalization of Rs. 63,239 Crores, the shares of Alkem Laboratories Limited were trading at Rs. 5,287, down 0.52 percent from its previous day’s close price of Rs. 5,311.15. 

Its revenue from operations grew by 9.08 percent from Rs. 10,634 Crores in FY22 to Rs. 11,599 Crores in FY23, accompanied by profits of Rs. 1,680 Crores to Rs. 1,007 Crores. 

In Q3FY24, the Foreign Institutional Investors/Foreign Portfolio Investors increased their holding in the company from 6.03 percent to 8.49 percent, by adding a 2.46 percent stake. 

According to the latest shareholding data available for the December 2023 quarter, the company’s Promoters hold 56.74 percent stake, the Domestic Institutional Investors hold 15.91 percent and the Foreign Institutional Investors (FII) hold 8.49 percent. 

Mankind Pharma 

Mankind Pharma Limited is one of the leading players in the pharmaceutical industry, it is engaged in developing, manufacturing, and selling a diverse range of markets pharmaceutical formulations across various acute, and chronic therapeutic areas and several consumer healthcare products.

With a market capitalization of Rs. 89,715 Crores, the shares of Mankind Pharma Limited were trading at Rs. 2,237.95, down 0.52 percent from its previous day’s close price of Rs. 2,249.75. 

Its revenue from operations grew by 8.56 percent from Rs. 7,486 Crores in FY22 to Rs. 8,127 Crores in FY23, accompanied by profits of Rs. 1,389 Crores to Rs. 1,248 Crores. 

In Q3FY24, the Foreign Institutional Investors/Foreign Portfolio Investors increased their holding in the company from 4.18 percent to 6.74 percent, by adding a 2.56 percent stake. 

According to the latest shareholding data available for the December 2023 quarter, the company’s Promoters hold 76.50 percent stake, the Domestic Institutional Investors hold 9.78 percent and the Foreign Institutional Investors (FII) hold 6.74 percent. 

Ami Organics 

AMI Organics (AMI) is one of the leading research and development-driven manufacturers of specialty chemicals, focused on the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients, New Chemical Entities, and key starting materials for agrochemical and fine chemicals. 

With a market capitalization of Rs. 4,015 Crores, the shares of Ami OrganicsLimited were trading at Rs. 1,088.60, down 1.64 percent from its previous day’s close price of Rs. 1,106.75. 

Its revenue from operations grew by 18.57 percent from Rs. 520 Crores in FY22 to Rs. 617 Crores in FY23, accompanied by profits of Rs. 72 Crores to Rs. 83 Crores. 

In Q3FY24, the Foreign Institutional Investors/Foreign Portfolio Investors increased their holding in the company from 7.15 percent to 11.66 percent, by adding a 4.51 percent stake. 

According to the latest shareholding data available for the December 2023 quarter, the company’s Promoters hold 39.91 percent stake, the Domestic Institutional Investors hold 7.58 percent and the Foreign Institutional Investors (FII) hold 11.66 percent. 

Written by: Bharath K.S

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.